Kangmei Chen1, Hanyi Min, Xiaopan Wu, Xilin Zhu, Zhuo Li, Hui Li, Ying Liu. 1. National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, P.R. China.
Abstract
AIMS: Janus kinase 1 (JAK1) is a key member in the interferon (IFN) signaling pathway. Recent studies suggested single-nucleotide polymorphisms (SNPs) in IFN pathway genes are associated with outcomes of hepatitis B virus (HBV) infection and response to IFNα therapy. The aim of the study is to investigate whether SNPs in JAK1 were associated with outcomes of HBV infection and response to IFNα therapy. METHODS: We enrolled 395 chronic hepatitis B (CHB) patients and 251 subjects with the inactive carrier state, and 256 CHB patients who received IFNα treatment, with therapy efficacy evaluated. Twelve SNPs: rs310227, rs7531799, rs7546545, rs17127174, rs3790541, rs10493373, rs2780898, rs310247, rs310196, rs2780895, rs4244165, and rs17127024 in JAK1, which could represent all SNPs with minor allele frequency >0.2 recorded in the HapMap database were genotyped using a polymerase chain reaction-restriction fragment length polymorphism protocol and the TaqMan method. RESULTS: SNP rs17127024 was associated with outcomes of HBV infection in an allele frequency (p=0.014) and genotype distributions (p=0.031), while SNP rs4244165 was associated with outcomes of HBV infection only in genotype distributions (p=0.008). There were no significant differences in allele frequencies and genotype distributions of these SNPs between the response group and the nonresponse group to IFNα therapy. CONCLUSIONS: SNPs rs4244165 and rs17127024 in JAK1 were associated with outcomes of HBV infection, but not with response to IFNα therapy.
AIMS: Janus kinase 1 (JAK1) is a key member in the interferon (IFN) signaling pathway. Recent studies suggested single-nucleotide polymorphisms (SNPs) in IFN pathway genes are associated with outcomes of hepatitis B virus (HBV) infection and response to IFNα therapy. The aim of the study is to investigate whether SNPs in JAK1 were associated with outcomes of HBV infection and response to IFNα therapy. METHODS: We enrolled 395 chronic hepatitis B (CHB) patients and 251 subjects with the inactive carrier state, and 256 CHB patients who received IFNα treatment, with therapy efficacy evaluated. Twelve SNPs: rs310227, rs7531799, rs7546545, rs17127174, rs3790541, rs10493373, rs2780898, rs310247, rs310196, rs2780895, rs4244165, and rs17127024 in JAK1, which could represent all SNPs with minor allele frequency >0.2 recorded in the HapMap database were genotyped using a polymerase chain reaction-restriction fragment length polymorphism protocol and the TaqMan method. RESULTS: SNP rs17127024 was associated with outcomes of HBV infection in an allele frequency (p=0.014) and genotype distributions (p=0.031), while SNP rs4244165 was associated with outcomes of HBV infection only in genotype distributions (p=0.008). There were no significant differences in allele frequencies and genotype distributions of these SNPs between the response group and the nonresponse group to IFNα therapy. CONCLUSIONS: SNPs rs4244165 and rs17127024 in JAK1 were associated with outcomes of HBV infection, but not with response to IFNα therapy.
Authors: Le H Song; Nguyen L Toan; Nguyen T Xuan; Anne-Catrin Uhlemann; Angelica B W Boldt; Dinh N Duy; Vu Q Binh; Peter G Kremsner; Jürgen F J Kun Journal: Mutat Res Date: 2006-08-21 Impact factor: 2.433
Authors: Jie Zhou; Liwei Lu; Man-Fung Yuen; Ting-Wa Lam; Chi-Ping Chung; Chun-Lit Lam; Bin Zhang; Song Wang; Yu Chen; Sharon H W Wu; Vincent K M Poon; Fai Ng; Chris C S Chan; Shibo Jiang; Kwok-Yung Yuen; Bo-Jian Zheng Journal: J Hepatol Date: 2006-10-17 Impact factor: 25.083
Authors: Eun Goo Jeong; Min Sung Kim; Hyo Kyung Nam; Chang Ki Min; Seok Lee; Yeun Jun Chung; Nam Jin Yoo; Sug Hyung Lee Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531